URB602 at doses of 20 and 40 mg/kg tends to reduce upper GI transit and slow colonic propulsion. When taken together as whole gut transit, URB602 dose dependently inhibits transit (P<0.05) compared with the vehicle control group. The inhibitory action of 40 mg/kg URB602 on whole gut transit is absent in these mice, indicating CB₁ receptor involvement in the inhibitory action^[3]. URB602 decreases the AUC of pain behaviour during the early phase of the formalin test with an ED₅₀ of 0.06±0.028 μg for JZL184 and 120±51.3 μg for URB602 in adult male Sprague-Dawley rats. Both MGL inhibitors also suppresses pain behaviour during the late phase of formalin pain, with an ED₅₀ of 0.03±0.011 μg for JZL184 and 66±23.9 μg for URB602^[4].